---
title: "BLSM: Q2 2026 net loss widened to $23.8M as R&D ramped up; IPO raised $151.7M for future operations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299441702.md"
description: "Q2 2026 saw increased R&D spending and a net loss of $23.8M, driven by clinical trial expansion for lead oncology programs. The company completed an IPO in August, raising $151.7M, and expects current funds to support operations into Q2 2028.Original document: BlossomHill Therapeutics, Inc. [BLSM] SEC 10-Q Quarterly Report — Sep. 18 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-09-18T11:31:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299441702.md)
  - [en](https://longbridge.com/en/news/299441702.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299441702.md)
generator: "portal-rs"
---

# BLSM: Q2 2026 net loss widened to $23.8M as R&D ramped up; IPO raised $151.7M for future operations

Q2 2026 saw increased R&D spending and a net loss of $23.8M, driven by clinical trial expansion for lead oncology programs. The company completed an IPO in August, raising $151.7M, and expects current funds to support operations into Q2 2028.

Original document: BlossomHill Therapeutics, Inc. \[BLSM\] SEC 10-Q Quarterly Report — Sep. 18 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [BLSM.US](https://longbridge.com/en/quote/BLSM.US.md)

## Related News & Research

- [BlossomHill Partners With Foundation Medicine to Develop Companion Diagnostic for BH-30643](https://longbridge.com/en/news/302703131.md)
- [BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Sees Significant Increase in Short Interest](https://longbridge.com/en/news/301514983.md)
- [Is Elevance Health (ELV) Still Undervalued Following Strong Earnings And Higher 2026 Guidance?](https://longbridge.com/en/news/302983253.md)
- [Xencor Reports 45.5% Confirmed Response Rate for XmAb819 at Selected Dose in Phase 1 Kidney Cancer Trial](https://longbridge.com/en/news/302982565.md)
- [Goldman Sachs Trims Blackstone Price Target to $125, Maintains Hold on Back-End-Loaded Growth and Valuation Risk](https://longbridge.com/en/news/302979730.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**